Table 4.
Univariate analysis of the treatments used in patients with or without concomitant SARS-CoV-2 (COVID-19) that were included in a retrospective case–control study that aimed to identify the strains of carbapenem-resistant Enterobacteriaceae and the risk factors associated with acquiring these infections.
| Patients’ treatment | Patients with COVID-19n = 38 | Patients without COVID-19n = 26 | Statistical analysisa |
|---|---|---|---|
| Treatment with reserve antibiotics | 29 (76.32) | 13 (50.00) | P = 0.029 |
| Ceftazidime-avibactam | 4 (10.53) | 2 (7.69) | NS |
| Colistin | 4 (10.53) | 3 (11.54) | NS |
| Carbapenem | 21 (55.26) | 4 (15.38) | P = 0.001 |
| Cephalosporins | 10 (26.32) | 4 (15.38) | NS |
| Piperacillin-tazobactam | 1 (2.63) | 1 (3.85) | NS |
| Quinolones | 16 (42.11) | 3 (11.54) | P = 0.009 |
| Linezolid | 9 (23.68) | 1 (3.85) | P = 0.032 |
| Vancomycin | 1 (2.63) | 6 (23.08) | P = 0.010 |
| Metronidazole | 1 (2.63) | 8 (30.77) | P = 0.001 |
| Aminoglycosides | 5 (13.16) | 5 (19.23) | NS |
| Doxycycline | 5 (13.16) | 1 (3.85) | NS |
| Azithromycin | 1 (2.63) | 0 (0.00) | NS |
| Corticosteroids | 32 (84.21) | 11 (42.31) | P < 0.001 |
Data presented as n of patients (%).
aχ2-test; NS, no significant between-group difference (P > 0.05).